Clinical Trial of Gimsilumab for COVID-19 Patients Underway
Temple University Health System
Gimsilumab is a fully human monoclonal antibody targeting granulocyte macrophage-colony stimulating factor, which is believed to be a key driver of lung hyper-inflammation